Etzer Darout, an analyst from BMO Capital, has initiated a new Buy rating on Jasper Therapeutics (JSPR).
Etzer Darout has given his Buy rating due to a combination of factors, primarily focusing on the promising developments surrounding Jasper Therapeutics’ lead program, briquilimab. The ongoing clinical trials, such as the BEACON and SPOTLIGHT studies, have shown encouraging signs of efficacy and safety in treating chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), which are key areas of interest for the company.
Furthermore, the initiation of the ETESIAN trial in allergic asthma and the anticipated registrational trial in CSU in the second half of 2025 highlight the potential for expanding briquilimab’s indications. The company’s financial position, with cash reserves expected to sustain operations through the end of 2025, also supports a positive outlook. These factors collectively underpin Darout’s confidence in the stock’s potential, leading to the Buy rating.
Darout covers the Healthcare sector, focusing on stocks such as Q32 Bio, Protagonist Therapeutics, and Jasper Therapeutics. According to TipRanks, Darout has an average return of 27.7% and a 50.64% success rate on recommended stocks.